# Delve Bio

> Delve Bio is a Boston diagnostics company commercializing metagenomic next-generation sequencing for serious central nervous system infections. Its flagship Delve Detect service sequences DNA and RNA from cerebrospinal fluid, compares the reads with a curated database covering more than 68,000 pathogens, and returns a clinically reviewed report after sample receipt. The wager is that a broad, hypothesis-free test can replace part of the serial culture-and-PCR hunt that delays answers in meningitis and encephalitis.

- **Founded:** 2022
- **Headquarters:** Boston, United States
- **Founders:** Brad Murray (Co-Founder and CEO), Charles Chiu (Co-Founder and Scientific Advisor), Joe DeRisi (Co-Founder), Michael Wilson (Co-Founder and Director), Pardis Sabeti (Co-Founder), Matthew Meyerson (Co-Founder)
- **Team size:** Approximately 43-45 employees; LinkedIn lists 11-50 and displayed 45 employees in 2026.
- **Products:** Delve Detect CSF, Delve Decide, Clinical Microbial Sequencing Board, Sample transfer and reporting workflow
- **Notable:** Secured an exclusive UCSF license for a clinically validated CSF metagenomic sequencing platform., Raised a $35 million Series A in June 2023., Partnered with Broad Clinical Labs in October 2024 to scale sample processing and sequencing.

## Products & services

- **Delve Detect CSF** — A laboratory-developed metagenomic sequencing service that analyzes DNA and RNA from 1 mL of cerebrospinal fluid for bacteria, viruses, fungi and parasites, with results targeted within 48 hours after receipt.
- **Delve Decide** — The proprietary bioinformatics and clinical-interpretation platform behind Delve Detect, including a curated database of more than 68,000 known and emerging pathogens.
- **Clinical Microbial Sequencing Board** — On-call infectious-disease and microbiology expertise that helps ordering clinicians interpret sequencing findings in clinical context.
- **Sample transfer and reporting workflow** — Free room-temperature CSF transfer kits, expedited return shipping, ordering support and clinical reporting for institutional laboratories.

## Achievements

- Secured an exclusive UCSF license for a clinically validated CSF metagenomic sequencing platform.
- Raised a $35 million Series A in June 2023.
- Partnered with Broad Clinical Labs in October 2024 to scale sample processing and sequencing.
- Commercially launched Delve Detect in December 2024 with a 48-hour turnaround target after sample receipt.
- Supported publication of a Nature Medicine study spanning 4,828 tests and 437 unique pathogen species.
- Demonstrated viral subtyping and strain-differentiation capabilities from Delve Detect sequence data in 2025.
- Presented 2026 case data in which mNGS identified pathogens after culture or panel testing was negative.

## Latest updates

- **2026-06** — Published case-based evidence describing management of elusive CNS pathogens, including diagnoses that helped avoid invasive procedures.
- **2026-04** — Presented AAN data on additional organisms missed by syndromic panels and case reports where results changed treatment decisions.
- **2026-01** — Announced a modeling study suggesting earlier mNGS could avoid 64% of microbiology tests and save nearly seven days in an infectious cohort.
- **2025-11** — Presented AMP findings on clinical impact in complex CNS infections, including co-infection and culture-negative presentations.
- **2025-05** — Reported that Delve Decide could subtype selected viruses and provide strain-level context from sequence data.

## Links

- Website: https://www.delve.bio
- LinkedIn: https://www.linkedin.com/company/delve-bio
- Twitter/X: https://x.com/DelveBio

---

Profile page: https://yespress.io/delve-bio
Published by YesPress — https://yespress.io
Last updated: 2026-08-20